Meta(bolite) analysis

How delivered gut metabolites could yield a pan-food allergy therapy

ClostraBio Inc.’s preclinical gut microbiome-derived metabolites could yield a pan-allergen therapy for food allergy, eschewing the need for multiple allergen-specific treatments.

Director of Operations John Colson said research from co-founder and President Cathryn Nagler suggests microbial imbalance and gut barrier permeability drive the allergen sensitization that leads to food allergy. Nagler is also a food allergy professor at the University of Chicago.

Nagler and Harvard Medical School assistant

Read the full 662 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE